Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or ...
InMed Pharmaceuticals (Nasdaq:INM) recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results